Walleye Capital’s Immunocore IMCR Stock Holding History

Walleye Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-89,208	Closed	-$3.02M	–	5552
2024 Q2	$3.02M	Buy	89,208 +88,977	+38,518%	+$4.54M	0.01%	1717
2024 Q1	$15K	Buy	+231	New	+$15.9K	﹤0.01%	4989

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Walleye Capital's IMCR Position: Q3 2024 in Review

Walleye Capital sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 89,208 shares — an estimated $3.02M sold.

Walleye Capital first reported a position in IMCR in Q1 2024 and held it in 2 quarters. The position peaked at $3.02M in Q2 2024. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

Walleye Capital reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 89,208 Immunocore shares in Q3 2024, an estimated $3.02M.
Walleye Capital first reported a position in Immunocore in Q1 2024 and held it in 2 quarters.
Walleye Capital's Immunocore position peaked at $3.02M in Q2 2024.
130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.